{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["gemcitabine","oxaliplatin"]],"indication":"resectable pancreatic cancer","name":"NEOPAC","nct_id":"NCT01314027","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neopac-nct01314027. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine","label":"neoadjuvant + adjuvant chemotherapy","type":"EXPERIMENTAL"},{"description":"adjuvant therapy is based on gemcitabine","label":"adjuvant chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2019-05","type":"ACTUAL"},"conditions":["Pancreatic Cancer"],"enrollment":{"count":38,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin","otherNames":["gemcitabine","eloxatin"],"type":"DRUG"},{"name":"adjuvant chemotherapy with gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2019-07-25","lead_sponsor":"University of Zurich","official_title":"Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"9 months after inclusion"}],"references":[{"citation":"Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.","pmid":"21831266","type":"DERIVED"}],"start_date":{"date":"2009-09"},"study_type":"INTERVENTIONAL","title":"Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT01314027"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neopac-nct01314027"}